Erasca (NASDAQ:ERAS) Sets New 1-Year High – Time to Buy?

30 Jan 2026, 20:22 by Tristan Rich · The Markets Daily

Erasca, Inc. (NASDAQ:ERAS – Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $10.70 and last traded at $10.2530, with a volume of 6906 shares traded. The stock had previously closed at $10.50.

Analyst Upgrades and Downgrades

ERAS has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research note on Thursday, January 22nd. Morgan Stanley set a $10.00 target price on shares of Erasca in a research report on Monday. HC Wainwright upped their price target on shares of Erasca from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Monday. Guggenheim reiterated a “buy” rating and issued a $12.00 price target on shares of Erasca in a research note on Tuesday. Finally, Piper Sandler upped their target price on Erasca from $5.00 to $11.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Erasca presently has an average rating of “Moderate Buy” and an average target price of $9.22.

Read Our Latest Analysis on ERAS

Erasca Trading Up 1.3%

The firm’s 50-day moving average price is $5.20 and its 200 day moving average price is $3.07. The company has a market cap of $3.23 billion, a price-to-earnings ratio of -23.21 and a beta of 1.15.

Erasca (NASDAQ:ERAS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). Analysts forecast that Erasca, Inc. will post -0.73 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Ebun Garner sold 120,000 shares of Erasca stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the transaction, the general counsel directly owned 25,076 shares in the company, valued at $140,174.84. This trade represents a 82.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.40% of the stock is owned by corporate insiders.

Institutional Trading of Erasca

Several institutional investors and hedge funds have recently modified their holdings of ERAS. Vivo Capital LLC boosted its position in shares of Erasca by 37.2% during the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company’s stock valued at $20,216,000 after buying an additional 2,516,672 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in Erasca by 13.9% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company’s stock worth $29,561,000 after acquiring an additional 1,652,835 shares during the last quarter. VR Adviser LLC grew its stake in shares of Erasca by 10.1% in the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after acquiring an additional 1,640,867 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in shares of Erasca by 22.3% in the second quarter. Affinity Asset Advisors LLC now owns 4,085,787 shares of the company’s stock valued at $5,189,000 after purchasing an additional 744,268 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Erasca by 594.8% during the first quarter. AQR Capital Management LLC now owns 396,202 shares of the company’s stock valued at $543,000 after purchasing an additional 339,177 shares in the last quarter. 67.78% of the stock is owned by hedge funds and other institutional investors.

Erasca Company Profile

(Get Free Report)

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.